A case report of a lung transplant recipient receiving belatacept in combination with low dose tacrolimus complicated by progressive multifocal leukoencephalopathy.

Vahdatpour C, Saha B, Younis M, Montuoro C, Timofte I, Rackauskas M, Emtiazjoo A

Abstract readCase Reports

In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vahdatpour CDepartment of Medicine, Pulmonary Hypertension Program, University of Pennsylvania, USA.

Saha BDepartment of Pulmonary Critical Care Medicine, University of Florida, USA.

Younis MDepartment of Pulmonary Critical Care Medicine, University of Florida, USA.

Montuoro CDepartment of Pulmonary Critical Care Medicine, University of Florida, USA.

Timofte IDepartment of Pulmonary Critical Care Medicine, University of Texas Southwestern, USA.

Rackauskas MDepartment of Surgery, Division of Thoracic Surgery, University of Florida, USA.

Emtiazjoo ADepartment of Pulmonary Critical Care Medicine, University of Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Belatacept is a novel T-cell costimulation blockade agent that has unresolved controversy in lung transplant recipients. Belatacept has been recognized as a calcineurin sparing agent for solid organ transplant recipients after reported success in renal transplant patients, despite limited evidence in other transplant recipients. We present the first case of a lung transplant recipient receiving Belatacept, in combination with low dose calcineurin inhibitor, who developed progressive multifocal leukoencephalopathy. While Belatacept without calcineurin inhibitor has been associated with increased risk of acute rejection in solid organ transplant recipients, its infectious risk profile in combination with calcineurin inhibitor remains unclear.

Identifiers

PMID38712316

DOI10.1016/j.rmcr.2024.102028

PMCPMC11070908

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.